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Abstract
Iodine-131 is successfully used in the treatment of hyperthy-
roidism and differentiated thyroid cancer. Thyroid is the critical 
organ for iodine. Iodine is taken up by the thyroid follicular cells. 
Radioactive isotope iodine-131 simultaneously emits two types 
of radiation: radiation beta minus (b-) used for the treatment and 
gamma (g) used for diagnosis. Due to the penetration of beta 
particles in tissue, damaging effect of b-radiation is restricted to 
thyroid cells. In this article, characteristic of iodine-131, mecha-
nism of action and mechanism of tissue damage is presented.
HIGH energy g-ray emission, contributes to the dose of both: pa-
tient’s body and the personnel. In accordance with the principles 
of radiation protection, reducing exposure to ionizing radiation 
should be achieved by: use of proper shieldings, organization 
of work, appropriate distance from the radiation source and 
reducing the time of exposure. Treatment with I-131, depend-
ing on medical indications, may be carried out on stationary 
or outpatient basis. All activities conducted in the exposure to 
radiation must comply with the principles of radiation protec-
tion, in accordance with the applicable regulations, that are also 
presented in this article.
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I-131 — physical and biological basis for 
therapy
Iodine-131 is successfully used in the treatment of hyperthy-
roidism and differentiated thyroid cancer. Advantages of iodine 
include: good tolerability, ease of application, safety and efficacy 
of therapy. Currently, iodine-131 is available as sodium iodide in 
gelatine capsules and drinking solution for oral application as well 
as in intravenous injections. Thyroid is the critical organ for iodine. 
Iodine is taken up by the thyroid follicular cells. Retention of iodine 
in the cells depends on the metabolic activity of the cells. It is as-
sumed that 30 % of iodine is trapped by the thyroid, and 70% 
directly excreted in the urine [1, 2].
Radioactive isotope iodine-131 simultaneously emits two 
types of radiation: radiation beta minus (b–) used for the treatment 
and gamma (g) used for diagnosis (Table. 1). Physical half-life 
(Tf) I-131 is 8.04 day. With regard to living organisms it should be 
taken into account that the biological half-life (Tb) of iodine in the 









effective half-life (Te) of iodine in the living body is about 7.6 day 
(Table 1) [3, 4].
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Table 1. Physical properties of iodine-131 [2]
Type of radiation emitted Energy Percentage
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The electrons are carriers of b– radiation. Electrons store their 
energy in form of kinetic energy that determines their speed. 
While passing through matter, electrons interact with it thanks to 
its electric charge. The b– electrons interact with electrons and 
atomic nuclei of the matter (Figure 1). b– radiation interaction with 
nuclei of the matter leads to the conversion of the electron energy 
into X-ray energy. This phenomenon is called deceleration of the 
electrons (bremsstrahlung). Significant deceleration radiation 
is characteristic for the matter of high atomic number (Z), i.e. for 
heavy materials such as lead, uranium, tungsten, and for large 
nuclei. b– radiation interaction with matter of low atomic number 
(human tissue) is essential for the radionuclide therapy. In this case, 
the most important is the interaction between b-ray electrons and 
atomic electrons of the matter. If an electron of b– radiation is near 
an electron of the matter, then they will repel each other, because 
both have the same charge. In many cases, the repelling force 
is significant to drive the electron out of its shell in the atom, and 
thus ionize the atom.
In materials of low atomic number, electrons of b– radiation 
lose about 33 keV of their energy to cause a single ionization. 
Typical b– electron with energy of several hundred keV, therefore, 
can cause multiple ionizations before it loses all its energy. Energy 
of b– electrons is transferred to the ionization as well as excitation 
of atoms of the matter (Figure 2).
The penetration of electrons in a tissue depends on the electron 
energy and density of the tissue, so it is characteristic of each 
radioactive isotope. For I-131, penetration of electrons in soft tis-
sue is about 1 mm (Figure 3). This means that the energy of the 
electron radiation is absorbed very close to the source of radiation.
The linear energy transfer (LET) is a measure of the energy 
transferred to material as an ionizing particle travels through it. 
LET in soft tissue for several different electron energy is given in 
the table below [2, 4]. Thus, for electrons emitted by I-131 LET 
is approximately 0.25 keV/µm (Table 2).
The effectiveness of the biological damage caused by corpus-
cular radiation is dependent on the value of LET. Radiation with 
high LET deposits more energy in tissue than needed to induce 
biological effects [4].
Due to the penetration of beta particles in tissue, damaging 
effect of b-radiation is restricted to thyroid cells. Adjacent cells are 
not exposed to significant radiation. The normal biodistribution 
of iodine include: salivary glands, stomach, intestines, urinary 
tract including the bladder (Figure 4). Therefore they receive rela-
tively high dose during therapy. High energy g-ray emission, also 
contributes to the dose to the entire body as well as exposure to 
personnel [2].
Interaction of ionizing radiation with living matter takes place 
in three successive phases (Table 3):
 — physical phase — radiation causes ionization or excitation 
of cells, which in turn leads to breaking of chemical bonds. 
As a result, free radicals are formed that further ionize the cell, 
or a direct damage to proteins, DNA and other components of 
the cell occurs;
 — chemical phase — free radicals and other products of the 
radiation react with cell components;
 — biological phase — the cells have their own mechanisms to 
control and repair DNA. Biological phase begins with the 
enzymatic reactions, which aim to repair chemical damage 









Figure 2. Trace of the electron in the matter, damage to DNA
Figure 3. Penetration of the electron b– in the thyroid [5]
Table 2. LET for different electron energy [4]
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in the cell. These reactions may last seconds, days or weeks. 
Damage that is impossible to repair or is improperly repaired 
causes the cell death [1, 6].
Ionization and excitation of cells under the influence of radiation 
leads to the lethal or non-lethal effects. Cell death is usually caused 
by the fact that a double strand of DNA damage is repaired incorrectly 
or is not repaired at all. As a result of changes in the DNA chain, while 
trying to activate mitosis, so-called reproductive cell death occurs. 
Many healthy as well as malignant cells undergo radiation-induced 
apoptosis. Apoptosis is a natural, programmed cell death [1]. 
Non-lethal effects include: genetic damage (mutations), impaired 
function of enzymes that normally do not lead to cell death.
Biological effects of exposure to radiation can also be divided 
into the effects of stochastic and non-stochastic (deterministic) 
(Table. 4) [1, 7, 8].
According to the ICRP 53 report “Radiation dose to pa-
tients from radiopharmaceuticals”, dose for an adult (> 20 years) 
subjected to treatment with I-131 (sodium iodide) is 18.4 mSv/MBq, 
which corresponds to the effective dose value of 10.4 mSv/MBq. 
In the case of 131I-MIBG therapy the values are 0.15 mSv/MBq 
and 0.21 mSv/MBq respectively [9, 10].
Guidelines for safe radionuclide therapy 
using I-131
In accordance with the principles of radiation protection, 
reducing exposure to ionizing radiation should be achieved by:
 — use of proper shieldings. A shield should be adapted to the 
type of radiation. Due to the deceleration radiation, the best 
shield for beta radiation is double-layered shield, the first 
layer of light material (small Z number, such as plexiglass), 
the second material with a high atomic number, such as lead. 
The best shields against photon radiation (X and gamma) are 
materials with large Z number. When designing the covers, it 
should be remembered that the patient who undergoes ra-
dioiodine therapy is a source of photon radiation, because 
the b– radiation used for therapy is entirely absorbed by the 
human body;
 — organization of work at an appropriate distance from the radia-
tion source, because the dose decreases with the square of 
the distance (the farther the safer)
 — reducing the time of exposure to radiation since dose in-
creases in direct proportion to exposure time.
Treatment with I-131, depending on medical indications, may 
be carried out on stationary or outpatient basis. In Poland, for the 
outpatient treatment with open sources of iodine-131, the applied 
activity may not exceed 800 MBq (in accordance with the appli-
cable regulation [7]).
It is very important to minimize the exposure of young children, 
pregnant women and women in the reproductive age. Different 
cells have different sensitivity to radiation. Cells are most radio-
sensitive during division (high mitotic activity) and differentiation. 
This makes irradiation particularly dangerous for pregnant women 
and young children. Therefore, it is so important to protect these 
groups of patients. In the radionuclide therapy facility this is real-
ized by complying with the following principles:
 — no access to the facility for children under the age of 10, un-
less they are patients;
Figure 4. Physiological uptake of I-131
Table 3. Phases of ionizing radiation with matter
Interaction phase Duration
Physical: ionization and excitation, the formation  
of free radicals
10-13– 10-11 s
Chemical interaction between the product of physical 
and physico-chemical phases, and other components  
of the cell
10-3 s
Biological: change of the biological properties Days, years
Table 4. Biological effects of radiation exposure [1]
Characteristics Stochastic effects Non-stochastic effects
Dependence on the dose absorbed The frequency and probability of occurrence  
proportional to the dose
The severity of symptoms proportional  
to the dose
Examples Genetic mutations, cancer Marrow suppression, immune suppression, 
temporary or permanent sterility, cataract, death
Threshold dose No Yes
Whole body threshold dose – 0,5 Gy
Other conditions Effects may occur, but do not have to occur;  
the occurrence is described by probability distribution
After crossing the threshold dose effects are 
always present
Occurrence Can occur in people exposed to radiation  
and offspring of these people
Occur only in individuals exposed to radiation
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 — during stationary treatment, a patient can be released from 
a hospital only after the fall in activity in the body below the 
800 MBq;
 — patient’s housing and family condition should always be 
taken into account while deciding when to release him from 
the hospital;
 — in the case of stationary therapy, medical staff’s contact 
with the patients after administration of iodine-131 due to 
thyroid cancer, should be restricted to an absolute minimum, 
and visits to these patients should be prohibited during the 
24 hours after application of the nuclide.
If therapy doses exceeds 800 MBq are applied in a hospital, 
special wards for patients undergoing stationary therapy should 
be organized. Rooms for the patient should be up to double, and 
the distance between the beds of patients may not be less than 
1.5 m (in the absence of such a possibility a protective screen 
should be placed between patients). The patients’ rooms should 
be equipped with own sanitary facilities (if it isn’t possible, it is ac-
ceptable to designate and mark special facilities to be used by 
these patients). Sanitary facilities should be equipped with liquid 
soap, paper towels or hand dryers and disposable pads on the 
toilet seat. The patient should be advised in written how to proceed 
in the room [7, 8].
Patient undergoing radionuclide therapy should also receive 
written information about appropriate behaviour in relation to the 
immediate environment. Staff and patients residing in the ward 
should follow the instructions on reducing exposure to ionizing 
radiation. Information and instructions should be written in accord-
ance with the recommendations of the committee and external 
audit procedures in nuclear medicine, and the recommendations of 
the national consultant in the field of nuclear medicine. [7, 8].
Personnel involved in the radioiodine therapy belong to the 
group of staff professionally exposed to ionizing radiation. All 
activities conducted in the exposure to radiation must comply 
with the principles of radiation protection. In Poland, the dose 
limits for workers and members of the public are included in the 
applicable regulation [7, 11]. The analysis of literature and our own 
experience, shows that in practice the doses received by staff of 
facilities offering radioiodine therapy are much lower than the dose 
limits, as shown in Table 5 [10–12].
Medical staff using open sources of iodine (I-131) for treatment, 
should be subject to internal control of the content of radioactive 
iodine in the thyroid gland. The frequency of inspection should be 
made dependent upon the degree of risk of internal contamination 
with iodine (I-131) [7].
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Table 5. Exposure of personnel
Doses Effective dose Equivalent dose to hands
According to the literature 0,001–0,008 mSv/GBq 0,1–0,2 mSv/GBq
According to our measurements 0,005–0,009 mSv/GBq 0,1–0,5m Sv/GBq
Dose limit 20 mSv/year 500 mSv/year
(over the next five years globally 100 mSv)
